目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING FOCUS OF ORGAN PRESERVATION COMPANIES ON BRAND PROTECTION
4.2.2 RISING NUMBER OF ORGAN TRANSPLANT PROCEDURES
4.2.3 RISING INSTANCES OF MULTIPLE ORGAN FAILURE
4.3 RESTRAINT
4.3.1 HIGH COST ASSOCIATED WITH ORGAN TRANSPLANTATION
4.4 OPPORTUNITY
4.4.1 INCREASING GOVERNMENT INITIATIVES RELATED TO ORGAN TRANSPLANT AND ORGAN DONATION

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON ORGAN PRESERVATION MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON DEMAND FOR ORGAN PRESERVATION SOLUTIONS

6 GLOBAL ORGAN PRESERVATION MARKET, BY SOLUTION
6.1 OVERVIEW
6.2 UNIVERSITY OF WISCONSIN SOLUTION
6.3 CUSTODIOL HTK
6.4 COLLINS SOLUTION
6.5 CELSIOR SOLUTION
6.6 PERFADEX
6.7 CITRATE SOLUTION

7 GLOBAL ORGAN PRESERVATION MARKET, BY PRESERVATION TECHNIQUES
7.1 OVERVIEW
7.2 STATIC COLD STORAGE (SCS) TECHNIQUE
7.3 DYNAMIC COLD STORAGE
7.3.1 HYPOTHERMIC MACHINE PERFUSION
7.3.2 NORMOTHERMIC MACHINE PERFUSION
7.3.3 OXYGEN PERSUFFLATION

8 GLOBAL ORGAN PRESERVATION MARKET, BY ORGAN TYPE
8.1 OVERVIEW
8.2 KIDNEY
8.3 LIVER
8.4 HEART
8.5 LUNGS
8.6 OTHERS

9 GLOBAL ORGAN PRESERVATION MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS & CLINICS
9.3 ORGAN BANKS
9.4 OTHERS

10 GLOBAL ORGAN PRESERVATION MARKET, BY REGION
10.1 OVERVIEW
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 LATIN AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 SPAIN
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 GERMANY
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 AUSTRALIA
10.4.4 SOUTH KOREA
10.4.5 JAPAN
10.4.6 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ORGAN PRESERVATION MARKET
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT APPROVAL
11.6.2 ACQUISITION
11.6.3 PRODUCT LAUNCH
11.7 MAJOR PLAYERS FINANCIAL MATRIX
11.7.1 SALES (USD MILLION), 2020
11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020

12 COMPANY PROFILES
12.1 TRANSMEDICS GROUP, INC.
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 BRISTOL-MYERS SQUIBB COMPANY
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 CRYOLIFE, INC.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 XVIVO PERFUSION AB
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 ACCORD HEALTHCARE
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 DR. FRANZ KÖEHLER CHEMIE GMBH
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 21ST CENTURY MEDICINE
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 BIOLIFE SOLUTIONS INC
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 PARAGONIX TECHNOLOGIES, INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
12.11 WATERS MEDICAL SYSTEMS
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES

13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS